Clinical impact of intracoronary abciximab in patients undergoing primary percutaneous coronary intervention: an individual patient data pooled analysis of randomised studies

Heart, 03/23/2012

In ST–segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI), intracoronary abciximab administration, when compared with the intravenous standard route, can improve short–term clinical outcomes mainly by reducing the risk of death.


  • Individual data of 1198 patients enrolled in five trials were entered into the pooled analysis.
  • The primary endpoint of the study was the occurrence of all–cause death and reinfarction at 30–day follow–up.
  • Secondary endpoints were all–cause death, reinfarction and target–vessel revascularisation (TVR).


  • No significant heterogeneity was found across trials.
  • Compared with the intravenous route, intracoronary abciximab administration significantly reduced the risk of the composite of death and reinfarction (HR 0.52, 95% CI 0.29 to 0.94; p=0.03), death (HR 0.44, 95% CI 0.20 to 0.95; p=0.04) and TVR (HR 0.53, 95% CI 0.29 to 0.99; p=0.045), without a significant impact on the risk of reinfarction (HR 0.54, 95% CI 0.24 to 1.21; p=0.13).
  • However, after correction for baseline differences, only the composite of death/reinfarction and death remained significant.

Print Article Summary Cat 2 CME Report